Literature DB >> 30251374

Does the Geriatric Depression Scale measure depression in Parkinson's disease?

Francesca V Lopez1, Molly Split1, J Vincent Filoteo1,2,3, Irene Litvan3, Raeanne C Moore1,2, Eva Pirogovsky-Turk2, Lin Liu1,4, Stephanie Lessig1,3, Dawn M Schiehser1,2.   

Abstract

The Geriatric Depression Scale (GDS) is recommended for screening depression in individuals with Parkinson's disease (PD). Empirical evidence, however, is limited regarding its validity and factor structure in PD. Thus, the current study sought to evaluate the convergent and divergent validity of the GDS, as well as the structure and validity of the derived factors.
METHOD: Nondemented individuals with PD (n = 158) completed the GDS-30, and items were subjected to a principle component analysis. Geriatric Depression Scale total and factor scores were correlated with depression items from the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRSd) and Hamilton Rating Scale for Depression (HAMDd), as well as with the Apathy Scale (AS), State-Trait Anxiety Inventory (STAI), Modified Fatigue Impact Scale (MFIS), Parkinson's disease Sleep Scale, and a Subjective Cognitive Function composite score.
RESULTS: The GDS total score was strongly correlated with divergent neuropsychiatric measures (AS, r = 0.57; STAI, r = 0.66; MFIS, r = 0.60), while only moderately correlated with convergent measures (MDS-UPDRSd, r = 0.36; HAMDd, r = 0.32; Ps < 0.05). Linear regression analyses revealed standardized measures of anxiety, apathy, and fatigue independently predicted the GDS total score, while depression items (MDS-UPDRSd and HAMDd) failed to reach significance. Three independent factors were identified: Anxiety, Apathy, and Fatigue. These factors were significantly predicted by their respective convergent measures.
CONCLUSIONS: Taken together, our findings suggest that the GDS and its subscales appear to primarily measure anxiety, apathy, and fatigue in PD, or alternatively, these symptom dimensions may be predominant in PD-depression. Future research with clinically diagnosed samples is needed to confirm these initial findings.
© 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Parkinson's disease; anxiety; apathy; depression; factors; fatigue; validity

Mesh:

Year:  2018        PMID: 30251374     DOI: 10.1002/gps.4970

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  5 in total

1.  Longitudinal risk factors for developing depressive symptoms in Parkinson's disease.

Authors:  Tarek Antar; Huw R Morris; Faraz Faghri; Hampton L Leonard; Mike A Nalls; Andrew B Singleton; Hirotaka Iwaki
Journal:  J Neurol Sci       Date:  2021-08-12       Impact factor: 4.553

2.  Clinical evaluation and resting state fMRI analysis of virtual reality based training in Parkinson's disease through a randomized controlled trial.

Authors:  Farzin Hajebrahimi; Halil Aziz Velioglu; Zubeyir Bayraktaroglu; Nesrin Helvaci Yilmaz; Lutfu Hanoglu
Journal:  Sci Rep       Date:  2022-05-16       Impact factor: 4.996

3.  What does the Dementia Rating Scale-2 measure? The relationship of neuropsychological measures to DRS-2 total and subscale scores in non-demented individuals with Parkinson's disease.

Authors:  Francesca V Lopez; Lauren E Kenney; Adrianna Ratajska; Charles E Jacobson; Dawn Bowers
Journal:  Clin Neuropsychol       Date:  2021-11-15       Impact factor: 4.373

4.  Fatigue in Parkinson's Disease Associates with Lower Ambulatory Diastolic Blood Pressure.

Authors:  Vikas Kotagal; Ashley Szpara; Roger L Albin; Nicolaas I Bohnen
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

5.  Vietnamese Version of the Geriatric Depression Scale (30 Items): Translation, Cross-Cultural Adaptation, and Validation.

Authors:  Thong Van Nguyen; Kien Trung Nguyen; Phuong Minh Nguyen; Nghiem Minh Nguyen; Chi Lan Ly; Thang Nguyen; Minh Thi Tuyet Nguyen; Hoang Minh Le; Xuyen Thi Kim Nguyen; Nghi Huynh Phuong Duong; Richard C Veith; Tuan Van Nguyen
Journal:  Geriatrics (Basel)       Date:  2021-12-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.